The FDA has granted 501 (k) clearance to the EXENT® System, a fully automated device for assessing monoclonal gammopathies, ...
The FDA has accepted the new drug application (NDA) of the synthetic, targeted radiotherapeutic agent 177 Lu-edotreotide (ITM ...
At the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, Meara explored the ...
What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger ...
Targeted Therapies in Oncology | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback